This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm, without specification of site (controls excluding all cancers)
C3_SECONDARY_WITHOUT_SITESPEC_EXALLC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters
Cause of death: ICD-10
C80
Cause of death: ICD-9
199
Cause of death: ICD-8
199
Cancer registry: Topography ICD-O-3
C80
Cancer registry: Morphology ICD-O-3
ANY
Cancer registry: Behaviour codes
3
2 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints None
-
Remove individuals based on genotype QC
838
C3_SECONDARY_WITHOUT_SITESPEC_EXALLC
Control definitions
Control exclude
C3_CANCER, C3_CANCER_WIDE
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm, without specification of site (controls excluding all cancers)
based on the number of shared cases.
Broader endpoints:
- Malignant neoplasm, without specification of site
- Secondary uncertain malignant neoplasm (controls excluding all cancers)
- Secondary uncertain malignant neoplasm
- Malignant neoplasm (controls excluding all cancers)
- Malignant neoplasm
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 838 | 286 | 552 |
| Unadjusted prevalence (%) | 0.22 | 0.14 | 0.33 |
| Mean age at first event (years) | 70.38 | 68.16 | 71.54 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: C3_SECONDARY_WITHOUT_SITESPEC_EXALLC – Malignant neoplasm, without specification of site (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Malignant neoplasm, without specification of site (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.